CAESAREA, Israel, March 19, 2017 /PRNewswire/ --
Itamar Medical Ltd. (TASE: ITMR) wishes to clarify its recent pressrelease, "An Important Recognition in the US Market for the WatchPAT™ Device" from March 16th.
Certain language in the press release mistakenly implies that the new AASM clinical practice guideline formally endorses
Itamar Medical wishes to publicly and sincerely apologize for any potential misunderstanding and inconvenience this caused to the AASM, its members or their patients.
About Itamar Medical Ltd.
Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) that develops and markets innovative diagnostic and therapy solutions for sleep breathing disorders and cardiovascular conditions.
Contact: Gilad Glick Chief Executive Officer and President T: +972-4-6177000 [email protected]
SOURCE Itamar Medical Ltd
Subscribe to our Free Newsletters!
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...View All